Interim Data on Insmed's Arikace - Analyst Blog

A generic image of a stock chart
Credit: Shutterstock photo

Insmed Incorporated ( INSM ) provided an interim update from the ongoing two-year, open-label extension study - CLEAR-110 - on Arikace. The study is evaluating once-daily Arikace for the treatment of pseudomonas aeruginosa (Pa) in patients suffering from cystic fibrosis (CF).

The data from the study suggested that Arikace was well tolerated. Additionally, sustained improvement from baseline level in Forced Expiratory Volume in One Second (FEV1) and a sustained reduction in density of Pa sputum during treatment was also observed.

We remind investors that in Jul 2013, Insmed reported encouraging results from a phase III study on Arikace for the treatment of Pa in CF patients, when compared to twice-daily Novartis ' ( NVS ) TOBI (tobramycin inhalation solution). Insmed plans to submit marketing applications for Arikace in the EU and Canada by mid-2014.

Insmed is also conducting a phase II study evaluating Arikace in patients suffering from lung infections caused by non-tuberculous mycobacteria (NTM). The company completed enrollment for the study in Oct 2013.

Arikace enjoys orphan drug designation for the CF indication both in the U.S. and the EU. The U.S. Food and Drug Administration (FDA) has also granted orphan drug designation to Arikace for the treatment of NTM lung infections.

We are pleased with the progress in Arikace's development program as it could be the first product offering once-daily administration for both CF and NTM lung infections and would, therefore, provide patients with a more convenient treatment option.

Insmed, a biopharmaceutical company, currently carries a Zacks Rank #2 (Buy). Investors may also consider other biopharmaceutical companies like Biogen Idec Inc. ( BIIB ) and Alexion Pharmaceuticals, Inc. ( ALXN ) which sport a Zacks Rank #1 (Strong Buy).

ALEXION PHARMA (ALXN): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

INSMED INC (INSM): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More